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Introduction {#nan12492-sec-0005}
============

Paraneoplastic neurological syndromes are autoimmune‐mediated neurodegenerative diseases caused by autoantibodies and autoreactive T cells against specific tumour types [1](#nan12492-bib-0001){ref-type="ref"}. Paraneoplastic cerebellar degeneration (PCD) is associated with severe and progressive ataxia, dysarthria and nystagmus due to the loss of cerebellar Purkinje neurons [1](#nan12492-bib-0001){ref-type="ref"}, [2](#nan12492-bib-0002){ref-type="ref"}, [3](#nan12492-bib-0003){ref-type="ref"}. PCD associated with the paraneoplastic autoantibody Yo occurs mainly in breast or ovarian cancer patients [2](#nan12492-bib-0002){ref-type="ref"}. The pathogenesis of Yo‐PCD is not completely understood, but Purkinje neurone loss may occur due to autoreactive T cells [3](#nan12492-bib-0003){ref-type="ref"}, [4](#nan12492-bib-0004){ref-type="ref"}, [5](#nan12492-bib-0005){ref-type="ref"}, [6](#nan12492-bib-0006){ref-type="ref"}, [7](#nan12492-bib-0007){ref-type="ref"} and Yo autoantibodies [8](#nan12492-bib-0008){ref-type="ref"}, [9](#nan12492-bib-0009){ref-type="ref"}, [10](#nan12492-bib-0010){ref-type="ref"}, [11](#nan12492-bib-0011){ref-type="ref"}. Autoantibody Yo cross‐react with the cerebellar degeneration‐related proteins, CDR2 and CDR2Like (CDR2L) [1](#nan12492-bib-0001){ref-type="ref"}, [12](#nan12492-bib-0012){ref-type="ref"}, [13](#nan12492-bib-0013){ref-type="ref"}, which have approximately 50% sequence identity [12](#nan12492-bib-0012){ref-type="ref"}, [13](#nan12492-bib-0013){ref-type="ref"}. CDR2 and CDR2L are widely expressed in gynaecological tumours [14](#nan12492-bib-0014){ref-type="ref"}, [15](#nan12492-bib-0015){ref-type="ref"}, normal tissue [15](#nan12492-bib-0015){ref-type="ref"} and brain [16](#nan12492-bib-0016){ref-type="ref"}, [17](#nan12492-bib-0017){ref-type="ref"}, [18](#nan12492-bib-0018){ref-type="ref"}, where Yo recognizes the leucine zipper motif of CDR2 [19](#nan12492-bib-0019){ref-type="ref"}. In the cerebellum, CDR2 and CDR2L are present in neuronal cytoplasm and proximal dendrites of Purkinje neurons but little is known about their neuronal functions [16](#nan12492-bib-0016){ref-type="ref"}, [17](#nan12492-bib-0017){ref-type="ref"}, [18](#nan12492-bib-0018){ref-type="ref"}, [20](#nan12492-bib-0020){ref-type="ref"}. Functionally, CDR2 is connected to c‐myc and the expression of calcium modulator and buffer calbindin D~28k~ [17](#nan12492-bib-0017){ref-type="ref"}, [20](#nan12492-bib-0020){ref-type="ref"}, [21](#nan12492-bib-0021){ref-type="ref"}, whereas CDR2L is linked to plasma membrane signalling involving voltage‐gated calcium channel‐ (VGCC) or AMPA receptor‐mediated calcium flux regulation [20](#nan12492-bib-0020){ref-type="ref"}.

Maintenance of intracellular calcium homeostasis, signal transduction regulation and ATP production are critical for normal cell metabolism and mitochondrial homeostasis, and if these processes are deregulated or dysfunctional, neurodegeneration eventually occurs [22](#nan12492-bib-0022){ref-type="ref"}, [23](#nan12492-bib-0023){ref-type="ref"}, [24](#nan12492-bib-0024){ref-type="ref"}, [25](#nan12492-bib-0025){ref-type="ref"}. Dysfunction of voltage‐dependent anion channels (VDAC) or Na^+^/Ca^2+^ exchangers (NCX) [26](#nan12492-bib-0026){ref-type="ref"}, deregulation of the mitochondrial calcium buffering capacity through mitochondria permeability transition pore (MPTP) opening [22](#nan12492-bib-0022){ref-type="ref"}, [25](#nan12492-bib-0025){ref-type="ref"}, or the increase in cytochrome‐C and reactive oxygen species (ROS) signalling and production [23](#nan12492-bib-0023){ref-type="ref"}, [27](#nan12492-bib-0027){ref-type="ref"} can all lead to excessive mitochondrial calcium overload, which in turn increases the intracellular calcium levels and can thereby induce cell death [24](#nan12492-bib-0024){ref-type="ref"}. Calcium homeostasis is not only regulated by influx and efflux of calcium but also by the modulation of the availability of free intracellular calcium through calcium buffer molecules like calbindin D~28k~ [28](#nan12492-bib-0028){ref-type="ref"}. Calbindin D~28k~ depletion has been correlated to neurodegeneration in PCD [29](#nan12492-bib-0029){ref-type="ref"}, Parkinson\'s disease [21](#nan12492-bib-0021){ref-type="ref"} and Alzheimer\'s disease [30](#nan12492-bib-0030){ref-type="ref"}. Furthermore, in Purkinje neurons, calbindin D~28k~ serves as a functional biomarker, as it modulates intracellular calcium and regulates Purkinje neurone motor coordination precision [28](#nan12492-bib-0028){ref-type="ref"}, [31](#nan12492-bib-0031){ref-type="ref"}, [32](#nan12492-bib-0032){ref-type="ref"}, which is affected in Yo‐PCD patients. Recent experimental evidence suggests that Yo antibodies affect intracellular calcium homeostasis [20](#nan12492-bib-0020){ref-type="ref"}; however, the detailed mechanisms are still largely unknown. As current antineoplastic and immunosuppressive PCD treatment is inadequate [33](#nan12492-bib-0033){ref-type="ref"}, greater understanding of the mechanisms behind the Yo driven calcium homeostasis imbalance could potentially provide crucial knowledge for development of effective neuroprotective therapies. We, therefore, investigated whether binding of autoantibody Yo to CDR2 and CDR2L affected mitochondrial homeostasis by investigating the activity of the MPTP, VDAC, NCX and ROS, and the deregulated activity of cannabinoid 1 receptor (CB1R) in Purkinje neurons by using a rat‐based *ex vivo* PCD model of cerebellar organotypic slice culture (cOTSC). Clinically relevant compounds were used to modulate the assumed dysregulation of the calcium‐sensitive mitochondrial‐associated signalling.

Materials and methods {#nan12492-sec-0006}
=====================

Patient sera {#nan12492-sec-0007}
------------

Sera were obtained from four patients with gynaecological cancer and PCD who had Yo autoantibodies against CDR2 and CDR2L (anti‐Yo~1--4~) [12](#nan12492-bib-0012){ref-type="ref"} but lacked P/Q‐type VGCC antibodies [20](#nan12492-bib-0020){ref-type="ref"}. Four sex‐ and age‐matched nonparaneoplastic neurological syndrome sera (non‐hCDR~1--4~) and a pool of sera from 100 healthy donors (non‐hCDR~100p~) were used as controls. Sera were not heat‐inactivated before use. Control and anti‐Yo patient sera were collected before patients were treated for cancer or PCD and were stored at the PND Biobank \#133/2015 or the Biobank for diagnostic cancer marker \#188.05 with approval of the regional ethics committee, Western‐Norway.

Cerebellar organotypic slice culture {#nan12492-sec-0008}
------------------------------------

All procedures were performed according to the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals Norway (FOTS 20135149/20157494). Wistar Hannover GLAST rat pups (*n* = 224), age P10 to P15, were used for cOTSC preparation as previously described [20](#nan12492-bib-0020){ref-type="ref"} (Figure [1](#nan12492-fig-0001){ref-type="fig"} **A**). Briefly, following anaesthesia and decapitation, the cerebellum was rapidly transferred into ice‐cold EBSS solution (\#24010043; Gibco‐ThermoFisher Scientific, Waltham, MA, USA) containing 0.5% glucose (\#G8769; Sigma‐Aldrich, St. Louis, Mo, USA) and 10 mM HEPES (\#15630056; Gibco). Four cerebellar parasagittal slices (400‐μm thick) from the vermis were cut on NVSLM1 motorized advance vibroslice (WPI) and transferred onto membranes of 12‐mm^2^ Millipore cell culture inserts with 0.4‐μm pore size (\# PICMO1250, Millicell; Merck ‐ Millipore, Burlington, MA, USA) for each cerebellum (Figure [1](#nan12492-fig-0001){ref-type="fig"} **A**). Slices were maintained in 24‐well plates at the air/culture media interface consisting of 30% advanced DMEM/F12 solution (\#126340010; Gibco), 20% MEM solution (\#41090028; Gibco), 25% EBSS solution, 25% heat‐inactivated horse serum (\#H1138; Sigma), 1 mM [l]{.smallcaps}‐glutamine (\#35050038; Gibco), 5 mg/ml [d]{.smallcaps}‐glucose and 2% B‐27 serum‐free supplement (\#17504044, Gibco) and were incubated with 5% CO~2~ at 35°C. All culture medium was removed and replaced 24 h postslicing, and 75% of the medium was replaced every 48 h thereafter. The slices were allowed to recover for 7 days before commencement of treatment.

![*Ex vivo* paraneoplastic cerebellar degeneration (PCD) model. (**A**) The illustration shows the cutting planes of the cerebellar vermis including the incubation chamber to maintain the rat cerebellar organotypic slice culture (cOTSC), the basis of the *ex vivo* PCD model system. (**B**) Experimental design: 7 days' postpreparation, anti‐Yo/rCDR and compounds were co‐applied either immediately at PCD onset \[(1), red arrow\] or 4 days after PCD induction \[(2), post‐PCD, blue arrow\] for 6 days. The pathological progression of anti‐Yo/rCDR internalization was determined by immunohistochemical (IHC) staining of Purkinje neurons with biomarker calbindin at 4, 6 and 10 days of treatment. (**C**) Three to eight confocal images of 750 × 750 × 50 μm in each cOTSC slice for each treatment were scanned and the Yo antibody incorporation‐dependent slice pathology (4, 6 and 10 days) was analysed by counting Purkinje neurone somata in the Purkinje cell layer (PCL) immunohistochemically visualized by biomarker calbindin D~28K~ (magenta). Calbindin‐positive cells (Calb^+^) were calculated as number of Calb^+^ cells/mm^3^ and plotted for each group.](NAN-45-141-g001){#nan12492-fig-0001}

*Ex vivo* PCD model {#nan12492-sec-0009}
-------------------

Seven days postslicing, the cOTSC medium was replaced with medium containing; human serum positive for autoantibody Yo (anti‐Yo; hCDR2/2L; 4 μl/ml) or heat‐inactivated (56°C, 45 min) polyclonal affinity‐purified rabbit CDR antibodies (anti‐rCDR; 100 ng/ml) (Figure [1](#nan12492-fig-0001){ref-type="fig"} **B**). The hCDR model involved anti‐Yo and two controls, non‐hCDR~1--4~ and non‐hCDR~100p~. The rCDR model involved affinity‐purified rabbit polyclonal antibody against CDR2 (\#HPA023870; Sigma), CDR2L (\#HPA022015; Sigma), or CDR2/2L (1:1 mixture), and the antibody control rabbit immunoglobulin G (rIgG; \#12370, Millipore). Slices were collected 4, 6 or 10 days after commencement of treatment to evaluate the antibody effects (Figure [1](#nan12492-fig-0001){ref-type="fig"} **B**). Each independent experiment included positive (non‐hCDR~1--4~; non‐hCDR~100p~; rIgG) and negative (naive) controls to account for variations in cell survival between slice preparations and the experimental approaches (with and without sera, antibodies and compounds). All treatments were performed in triplicate or quadruplicate.

Purkinje neurone‐specific antibodies {#nan12492-sec-0010}
------------------------------------

As a control to evaluate the specificity of the cytotoxic nature of anti‐Yo internalization in PCD, we studied two Purkinje neurone‐specific antigens, GAD65 and PCP2 (also known as L7). cOTSC was treated with 1000 ng/ml mouse anti‐GAD65 (\#559931; BD Bioscience, Franklin Lakes, NJ, USA) or 1000 ng/ml rabbit anti‐PCP2 (\#M194; Takara Bio Inc., Kusatsu, Shinga, Japan) for 6 days. These concentrations were 10‐fold higher than the anti‐rCDR concentration used in the rCDR PCD model.

Neuropharmacology {#nan12492-sec-0011}
-----------------

Approaches 1 and 2 (Figure [1](#nan12492-fig-0001){ref-type="fig"} **B**): To evaluate the neuroprotective potential of compounds that modulate calcium‐sensitive mitochondrial‐associated signalling, we co‐applied the compounds with anti‐Yo/rCDR immediately at PCD onset (approach 1) or 4 days after PCD induction (approach 2); cultures were treated for 6 days. Compounds tested were AM281 \[IC~50~: 12 nM (CB1R), 4.2 μM (CB2R); \#1115, Tocris Bioscience, Bristol, UK\], benzamil \[IC~50~: approximately 100 nM (NCX); \#3380; Tocris\], butylated hydroxytoluene \[BHT; IC~50~: 3.5 μM (ROS); \#W218405; Sigma\], cannabidiol \[CBD; IC~50~: 3.35 μM (CB1R), 27.5 μM (CB2R); \#1570; Tocris\], CGP37157 \[IC~50~: 400 nM (NCX); \#1114; Tocris\], cyclosporin‐A \[CsA; IC~50~: 5 nM (MPTP); \#1101; Tocris\] and KB‐R7943 \[IC~50~: 700 nM (NCX~rev~), 5.5 μM (MCU); \#1244; Tocris\]. As this PCD model system is based on an interface hydrophilic PTFE membrane‐diffusion approach where the cOTSC is not submerged, the system behaves like an *in vivo* brain. Therefore, several test dosages were evaluated starting with 2.5‐fold of the IC~50~ value to determine effective, nontoxic doses if there was no literature guided initial dose selection available for this kind of culture system. Depending on the hydrophilic or hydrophobic nature of the used compounds, the effective dosage was determined between 2.5 to 200 times of the IC~50~ value.

MitoTracker {#nan12492-sec-0012}
-----------

cOTSC was incubated at 37°C in culture media with MitoTracker Deep Red FM (MTDR, 500 nM; \#M22426; Invitrogen, Carlsbad, CA, USA) or MitoTracker Red CM‐H2xROS (MTROS, 1 μM; \#M7513; Invitrogen) for 30 min before fixation to evaluate the mitochondrial membrane potential (Δψ) and ROS output under anti‐Yo as well as neuropharmacological treatment. As a positive control for increased O~2~ consumption, the mitochondrial protonophore uncouplers FCCP (2 μM; IC~50~: 11.5 μM; \#0453; Tocris) [34](#nan12492-bib-0034){ref-type="ref"} and BAM15 (500 nM; EC~50~: 270 nM; \#5737; Tocris) [35](#nan12492-bib-0035){ref-type="ref"} were added 15 min after MitoTracker application, respectively. Unbound/unreactive MitoTracker was removed by wash with prewarm 0.1 M PBS (37°C, 4 × 1 min) before fixation. The relative fluorescence intensity was quantified using Fiji Measurement tool by creating a Plot Profile of a selected region of interest and corrected the integrated density to mean fluorescence background.

Immunohistochemistry {#nan12492-sec-0013}
--------------------

To evaluate Purkinje neurone health at the end of the treatment, cOTSC was washed with prewarmed 0.1 M PBS (1 × PBS; \#70013016; Gibco) and fixed with 4% paraformaldehyde (PFA‐PBS, pH 7.2, \#28908, ThermoFisher Scientific) containing 0.5% sucrose for 4 h at 4°C. Slices were quenched with 1 × PBS containing 50 mM NH~4~Cl (PBS~N~, \#A9434, Sigma), permeabilized with 1% Triton X‐100 (\#T9284; Sigma) in PBS~N~ (60 min, 22°C), rinsed with PBS~N~ (3 × 15 min), and incubated with 2 μg/ml primary antibody to calbindin D~28K~ (\#C9848, mouse, Sigma; \#214005, guinea pig, SySy ‐ Synaptic Systems, Göttingen, Germany) for 2 days at 4°C in PBS~N~ containing 5% bovine serum albumin (BSA; \#A2153; Sigma), 0.2% Triton X‐100 and 100 μM glycine (\#G7126; Sigma). To visualize not only Purkinje neurons by biomarker calbindin, but also the 4--10 days lasting live uptake of anti‐Yo and anti‐rCDR, the slices were rinsed with PBS~N~ (3 × 15 min) and incubated with highly cross‐absorbed secondary antibodies: donkey anti‐mouse or anti‐guinea pig (Calb), donkey anti‐rabbit (rCDR) and donkey anti‐human (Yo) conjugated to CF^™^488/594/647‐Dye (1:400; \#20014, \#20115, \#20046, \#20015, \#20152, \#20047, \#20074, \#20075, \#20169, \#20170; Biotium, Fremont, CA, USA) for 2 days at 4°C in PBS~N~ containing 2.5% BSA. To remove unbound secondary antibody, slices were rinsed with PBS~N~ (3 × 15 min), and briefly tipped into MilliQ water before mounting in hardening PromoFluor Antifade Reagent (\#PK‐PF‐AFR1; Promikine ‐ PromoCell, Heidelberg, Germany). After 2 days of hardening at 18--21°C in the dark, slices were stored at 4°C until imaging as previously described [20](#nan12492-bib-0020){ref-type="ref"}. All slices for each experimental setup were stained simultaneously to minimize variations in immunoreactivity levels within the investigated groups.

Imaging {#nan12492-sec-0014}
-------

Z‐stack images were collected at 0.5--1 μm intervals with a DMI6000‐CS‐TCS‐SP5 microscope using a HC‐PL‐APO 20 × 0.75 IMM‐CORR‐CS2 objective to detect CF^™^488/594/647 dye emission and superimposed with LASAF software V2.5.1 (Leica Microsystems GmbH, Wetzlar, Germany). The fluorescence intensity was adjusted to 75% of the maximum in untreated naive control tissue for each experiment.

Quantification of Purkinje neurone pathology {#nan12492-sec-0015}
--------------------------------------------

The anti‐Yo‐induced pathological state was evaluated by assessment of functional biomarker calbindin, neurodegeneration marker Fluoro‐Jade‐C (0.001%, 30 min prior mounting; \#AG325; Millipore), and cell death marker propidium iodide (2 μM, 48 h prior to fixation; \#P3566; Invitrogen) as described by Brana and Noraberg [36](#nan12492-bib-0036){ref-type="ref"}, [37](#nan12492-bib-0037){ref-type="ref"}. The pathological progress was quantified by counting calbindin‐immunoreactive Purkinje neurone somata (Calb^+^ cells) manually (but blind) and automatically in 3--8 images of 750 × 750 × 50 μm in each slice for each treatment, experiment, and group with counts reported per mm^3^ (Figure [1](#nan12492-fig-0001){ref-type="fig"} **C**). The automatic count showed a discrepancy of approximately 5% compared to manual count; therefore, each experimental set was counted solely manually or automatically. The automatic count was performed with Fiji as previously described [20](#nan12492-bib-0020){ref-type="ref"}.

Data analysis and statistics {#nan12492-sec-0016}
----------------------------

All treatments were performed in triplicate or quadruplicate. Data were evaluated using the nonparametric Mann--Whitney *U*‐test (Graph‐Pad‐Prism 4.0 software, San Diego, CA, USA) with *P* \< 0.05 considered statistically significant.

Results {#nan12492-sec-0017}
=======

Rat cOTSC‐based *ex vivo* PCD model {#nan12492-sec-0018}
-----------------------------------

Yo antibody‐positive sera from four PCD patients, and purified rabbit polyclonal antibodies against the Yo antigens CDR2 and CDR2L were used to induce Purkinje neurone degeneration. The antibody‐induced Purkinje neurone pathology was evaluated by visualizing the targeted neurons with the functional biomarker calbindin D~28k~ (Calb). Confocal imaging 6 days after application of Yo antibody showed that the tested Yo^+^ sera reduced the Calb^+^ cell count by 70.7 ± 7.8% (Yo~1~) and 67.1 ± 7.0% (Yo~2~) relative to naive controls (Figure [2](#nan12492-fig-0002){ref-type="fig"} **A**). This effect was specific to anti‐Yo as none of the control sera (non‐hCDR~1--4~ and non‐hCDR~100p~) caused depletion of calbindin‐immunoreactive cells (Figure [2](#nan12492-fig-0002){ref-type="fig"} **A**). Similar results were obtained when purified rabbit polyclonal antibodies against CDR2 and CDR2L were used. Antibody against CDR2 reduced the Calb^+^ cell count by 62.4 ± 5.5% and antibody against CDR2L by 67.7 ± 5.7%, whereas antibodies against other Purkinje neurone‐specific proteins such as anti‐PCP2 or ataxia‐related anti‐GAD65 showed no loss of calbindin immunostaining (Figure [2](#nan12492-fig-0002){ref-type="fig"} **B**). To verify that the depletion of calbindin‐immunoreactive cells reflects neurodegeneration, we employed the marker Fluoro‐Jade‐C. After Yo antibody treatment, the few remaining Calb^+^ Purkinje neurons were neither positive for Yo incorporation nor the neurodegeneration marker Fluoro‐Jade‐C (Figure [2](#nan12492-fig-0002){ref-type="fig"} **C**). In contrast, the calbindin depleted Purkinje neurons showed strong Yo internalization, Jade‐C staining and shrunken cell bodies (Figure [2](#nan12492-fig-0002){ref-type="fig"} **C**1), but were negative for cell death marker propidium iodide (Figure [2](#nan12492-fig-0002){ref-type="fig"} **C**2), indicating that neurodegeneration had begun but that cell death had not yet occurred.

![Yo and rCDR antibody internalization depletes calbindin D~28k~ in rat Purkinje neurons. Significant depletion of calbindin‐immunoreactive cells was observed after (**A**) Yo antibody and (**B**) rCDR antibody incorporation, whereas control sera (non‐hCDR~1--4,100p~) but IgG controls showed no impact on the Calb^+^ cell count. (**B**) The incubation with antibodies against Purkinje neurone specific protein 2 (PCP2) or ataxia‐related GAD65 (1000 ng, 6 days) revealed no reduction in the Calb^+^ cell count. (**C**) Calbindin depleted Purkinje neurons were positive for the neurodegeneration marker Fluoro‐Jade‐C (\*, green) and showed high incorporation of Yo antibodies (\#, magenta) (**C1**). The cell death marker propidium iodine (\#) (**C2**, magenta) was not found either in Calb^+^ (yellow) or Jade‐C^+^ (green) Purkinje neurons after 6 days of Yo antibody incorporation. Scale bar 25 μm.](NAN-45-141-g002){#nan12492-fig-0002}

Yo antibody binding to CDR2/2L leads to deregulation of cyclophilin D‐dependent MPTP opening and increased ROS production {#nan12492-sec-0019}
-------------------------------------------------------------------------------------------------------------------------

Immunohistochemical staining revealed that CsA (1 μM), which inhibits the cyclophilin D‐dependent opening of the MPTP [22](#nan12492-bib-0022){ref-type="ref"}, abolished the CDR antibody associated loss of calbindin immunoreactivity when cultures were co‐treated at PCD onset (Figure [3](#nan12492-fig-0003){ref-type="fig"} **A**,**B**) and after PCD was established (Figure [3](#nan12492-fig-0003){ref-type="fig"} **C**; post‐PCD). CsA showed similar neuroprotective effects whether PCD was induced by human Yo^+^ PCD sera or by purified CDR antibodies and did not affect the counts of Calb^+^ cells in the control slices (Figure [3](#nan12492-fig-0003){ref-type="fig"} **A**--**C**) nor the Yo antibody internalization (Figure [3](#nan12492-fig-0003){ref-type="fig"} **D**). CsA co‐treatment reduced the numbers of shrunken Purkinje neurone cell bodies that showed high Yo antibody internalization. When cultures were treated with anti‐Yo and CsA simultaneously, most Yo^+^ cells had normal cell body size and were positive for calbindin (Figure [3](#nan12492-fig-0003){ref-type="fig"} **D**). BHT (10 μM), a ROS scavenger [38](#nan12492-bib-0038){ref-type="ref"}, was tested to confirm that Yo antibody internalization leads to deregulation of the mitochondrial calcium buffering capacity, indicated by the CsA data. At PCD onset, BHT completely prevented the depletion of calbindin‐immunoreactive cells caused by anti‐Yo~2--4~ and anti‐rCDR2/2L internalization but was less effective against anti‐Yo~1~, anti‐rCDR2 and anti‐rCDR2L‐induced pathology (Figure [3](#nan12492-fig-0003){ref-type="fig"} **A**,**B**). After PCD was established (post‐PCD), BHT treatment was able to reduce the loss of calbindin immunoreactivity caused by anti‐Yo~1--2~ and anti‐rCDR2/2L internalization, almost to baseline (Figure [3](#nan12492-fig-0003){ref-type="fig"} **C**). BHT had no impact on control tissue (Figure [3](#nan12492-fig-0003){ref-type="fig"} **A**--**C**) and did not prevent the internalization of Yo antibodies (Figure [3](#nan12492-fig-0003){ref-type="fig"} **D**). Under BHT treatment, the cell count of Purkinje neurons positive for both calbindin and anti‐Yo increased and Yo‐positive Purkinje neurons did not display shrunken cell bodies. In support of the results obtained with CsA, these data indicate that Yo antibody binding to CDR2 and CDR2L induces ROS over‐production potentially through calcium overload and effect on respiratory chain complex I [27](#nan12492-bib-0027){ref-type="ref"}.

![Yo antibody binding to CDR2 and CDR2L leads to deregulation of mitochondria permeability transition pore opening and reactive oxygen species (ROS) production. (**A**--**C**) Calb^+^ cells per mm^3^ in cerebellar organotypic slice culture in response to treatment with anti‐Yo/rCDR and co‐treatment with cyclosporin‐A (CsA, *n* = 5) and ROS scavenger butylated hydroxytoluene (BHT, *n* = 4). The antagonistic effects on anti‐Yo‐induced pathology are represented in panels **A**,**C**, and for anti‐rCDRs‐induced pathology in panels **B**,**C**. Panels **A**,**B**, are showing the data collected when the antagonists were directly applied at paraneoplastic cerebellar degeneration (PCD) onset and panels **C** when applied at day 4 after PCD pathology was established. The neuroprotective capacity of the tested compounds was evaluated after 6 days for both treatment strategies. CsA and BHT significantly reduced or abolished neurodegeneration‐related depletion of calbindin‐immunoreactive cells in both treatment strategies. Data are collected at treatment day 6 (onset‐PCD) or 4 and 10 (post‐PCD) and expressed as mean ± SEM \[\**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001; nonparametric two‐tailed paired Mann--Whitney\'s *U*‐test; asterisk (\*): significance to naive control; hash (\#): significance to anti‐Yo/rCDR\]. (**D**) z‐stack confocal micrographs collected at day 10 of treatment showed that CsA (middle row) and BHT (bottom row) co‐applied for 6 days from day 4 of Yo antibody incorporation (post‐PCD) were not affecting the uptake of anti‐Yo (green, left column) but reduced depletion of calbindin‐immunoreactive cells (magenta, middle column) in comparison to anti‐Yo incorporation alone (top row). Under CsA and BHT treatment, two types of Yo^+^ cells were observed: Yo^+^ cells (green) negative for calbindin (magenta) with shrunken Purkinje neurone somata and Yo^+^ cells (green) positive for calbindin (magenta, merge white) without Purkinje neurone somata shrinkage (right column). Scale bar 25 μm.](NAN-45-141-g003){#nan12492-fig-0003}

Yo antibody binding to CDR2 impacts CB1R activity {#nan12492-sec-0020}
-------------------------------------------------

CB1Rs are highly expressed in the cerebellar molecular layer [39](#nan12492-bib-0039){ref-type="ref"}, [40](#nan12492-bib-0040){ref-type="ref"}. The CB1R antagonist *AM281* (10 μM) completely rescued the depletion of calbindin‐immunoreactive cells induced by anti‐Yo~1/2~ and partially by anti‐Yo~3/4~ (anti‐Yo~3~: 24.0 ± 7.9%, *P* = 0.0010; anti‐Yo~4~: 28.0 ± 6.1%, *P* \< 0.0001; Figure [4](#nan12492-fig-0004){ref-type="fig"} **A**). However, AM281 caused a profound loss of calbindin‐positive cells in control cOTSC (50.6 ± 8.1%, *P* \< 0.001; Figure [4](#nan12492-fig-0004){ref-type="fig"} **A**). Besides AM281, we also tested the clinically used low‐potency CB1R inverse agonist CBD (10 μM) [41](#nan12492-bib-0041){ref-type="ref"}. CBD prevented the depletion of calbindin‐immunoreactive cells when PCD was induced by human Yo^+^ PCD sera (Figure [4](#nan12492-fig-0004){ref-type="fig"} **A**). The depletion of calbindin‐immunoreactive cells induced by anti‐rCDR was only partially rescued, and there were differences in the CBD protection level for the anti‐rCDR2, anti‐rCDR2L and anti‐rCDR2/2L treatments (Figure [4](#nan12492-fig-0004){ref-type="fig"} **B**). At PCD onset, CBD was less effective against anti‐rCDR2L than anti‐rCDR2 or anti‐rCDR2/2L (Figure [4](#nan12492-fig-0004){ref-type="fig"} **B**). cOTSC treated with a 1:1 mixture of anti‐rCDR2 and anti‐rCDR2L responded more favourably to the CBD treatment than cultures treated with anti‐rCDRs individually (CDR2 + CBD *vs*. CDR2/2L + CBD *P* = 0.0014; CDR2L + CBD *vs*. CDR2/2L + CBD *P* \< 0.0001; CDR2 + CBD *vs*. CDR2L + CBD *P* = 0.0874). In PCD free control slices, CBD caused a slight reduction in calbindin‐positive Purkinje neurons \[22.8 ± 4.1% (naive), 16.9 ± 3.1% (rIgG); *P* \< 0.001; Figure [4](#nan12492-fig-0004){ref-type="fig"} **B**\]. When CBD was applied after PCD was established, at day 4, depletion of calbindin‐immunoreactive cells was reduced in anti‐Yo and anti‐rCDR2/2L‐treated cultures but levels did not return to baseline control levels (*P* \< 0.001; Figure [4](#nan12492-fig-0004){ref-type="fig"} **C**). Furthermore, as seen for CsA and BHT also CBD reduced the anti‐Yo‐induced depletion of calbindin‐immunoreactive cells, including the anti‐Yo‐associated cell shrinkage but without preventing the antibody uptake in itself (Figure [4](#nan12492-fig-0004){ref-type="fig"} **D**).

![Yo antibody binding to CDR2 impacts cannabinoid 1 receptor activity. (**A**--**C**) Calb^+^ cells per mm^3^ in cerebellar organotypic slice culture in response to treatment with anti‐Yo/rCDR and co‐treatment with AM281 (*n* = 3) and cannabidiol (CBD, *n* = 6). The antagonistic effects on anti‐Yo‐induced pathology are represented in panels **A**,**C**, and for anti‐rCDRs‐induced pathology in panels **B**,**C**. Panels **A** and **B** are showing the data collected when the antagonists were directly applied at paraneoplastic cerebellar degeneration (PCD) onset and panels **C** when applied at day 4 after PCD pathology was established. The neuroprotective capacity of the tested compounds was evaluated after 6 days for both treatment strategies. AM281 and CBD minimized the Yo‐induced depletion of calbindin‐immunoreactive cells but caused depletion of calbindin‐immunoreactive cells in naive, IgG and serum controls, respectively. Data are collected at treatment day 6 (onset‐PCD) or 4 and 10 (post‐PCD) and expressed as mean ± SEM \[\**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001; nonparametric two‐tailed paired Mann--Whitney\'s *U*‐test; asterisk (\*): significance to naive control; hash (\#): significance to anti‐Yo/rCDR\]. (**D**) z‐stack confocal micrographs collected at day 10 of treatment showed that CBD co‐applied for 6 days from day 4 of Yo antibody incorporation (post‐PCD) was not affecting the uptake of anti‐Yo (green) itself (top row) but reduced depletion of calbindin‐immunoreactive cells (magenta, middle row) in comparison to Yo incorporation alone. Yo^+^ cells (green) negative for calbindin with shrunken Purkinje neurone somata as well as Yo^+^ cells (green) positive for calbindin (white) without Purkinje neurone somata shrinkage were observed under CBD treatment (bottom row). Scale bar 25 μm.](NAN-45-141-g004){#nan12492-fig-0004}

Yo antibody binding reduces mitochondrial membrane potential and increases ROS activity {#nan12492-sec-0021}
---------------------------------------------------------------------------------------

To support the pharmacological data, we performed a semiquantitative fluorescence intensity analysis of the mitochondrial membrane potential by using MitoTracker deep red (MTDR) and also ROS activity by using MitoTracker Red CM‐H2xROS (MTROS) (Figure [5](#nan12492-fig-0005){ref-type="fig"} **A**,**C**). *MTDR* signal was reduced by 71.76 ± 5.5% after 10 days of anti‐Yo internalization (*P* \< 0.001; Figure [5](#nan12492-fig-0005){ref-type="fig"} **B**). This anti‐Yo‐induced MTDR level reduction was similar to MTDR levels observed under protonophore uncoupler FCCP or BAM15 \[78.59 ± 10.9% (FCCP), 77.78 ± 14.5% (BAM15); *P* \< 0.001; Figure [5](#nan12492-fig-0005){ref-type="fig"} **B**\]. Following PCD initiation (post‐PCD condition), loss of MTDR fluorescence was decreased but not entirely prevented by CsA, BHT and CBD, whereas BHT showed the highest effectiveness, followed by CBD and then CsA \[MTDR fluorescence reduction: 48.87 ± 4.7% (Yo/CsA), 10.97 ± 4.9% (Yo/BHT), 26.21 ± 4.1% (Yo/CBD); *P* \< 0.001; Figure [5](#nan12492-fig-0005){ref-type="fig"} **B**\]. *MTROS* staining showed a 2‐fold increase after 10 days of anti‐Yo internalization \[1.904 ± 0.084 (*Yo*); *P* \< 0.001; Figure [5](#nan12492-fig-0005){ref-type="fig"} **D**\]. Under post‐PCD experimental settings, the anti‐Yo increased MTROS level was not altered by CsA (1.771 ± 0.098; *P* = 0.2977); it was reduced to control level by BHT (0.956 ± 0.063; *P* \< 0.0001) and potentiated by CBD (2.701 ± 0.1404; *P* \< 0.001) (Figure [5](#nan12492-fig-0005){ref-type="fig"} **D**). Interestingly, the MTROS signal was not affected by protonphore uncoupler BAM15 but significantly increased by FCCP (1.816 ± 0.075; *P* \< 0.001).

![Yo antibody binding to CDR2 and CDR2L reduces mitochondrial membrane potential and boosts reactive oxygen species (ROS) production. At day 10 of postparaneoplastic cerebellar degeneration treatment, Purkinje neurons were loaded with (**A**,**B**) MitoTracker Deep Red (MTDR) or (**C**,**D**) MitoTracker Red CM‐H2xROS (MTROS) and stained for calbindin D~28k~ (Calb). (**A**,**C**) Representative line‐scan plot across a single Purkinje neurone from soma to dendritic tree in the molecular cell layer showing the fluorescence dissipation of (**A**) MTDR (blue) and (**C**) MTROS (green) neuroanatomy‐dependent indicated by the calbindin (red) fluorescence course in an untreated control (ctrl) slice *vs*. a slice that had internalized anti‐Yo (Yo). (**B**,**D**) Relative fluorescence intensity of (**B**) MTDR and (**D**) MTROS normalized to control in response to treatment with anti‐Yo and co‐treatment with cyclosporin‐A (CsA, *n* = 3), ROS scavenger butylated hydroxytoluene (BHT, *n* = 3) and cannabidiol (CBD, *n* = 3). (**B**) Anti‐Yo internalization reduced the mitochondrial membrane potential (Δψ) similar to protonophore uncoupler FCCP or BAM15. CSA, BHT and CBD prevented partially the anti‐Yo induced Δψ reduction (**D**) Anti‐Yo internalization enhanced ROS production which was suppressed by BHT treatment, unaffected by CSA and potentiated by CBD. Data are collected at treatment day 10, expressed as mean ± SEM and normalized to control \[\**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001; nonparametric two‐tailed paired Mann--Whitney\'s *U*‐test; asterisk (\*): significance to naive control; hash (\#): significance to anti‐Yo\].](NAN-45-141-g005){#nan12492-fig-0005}

Yo antibody binding to CDR2L deregulates NCX signalling {#nan12492-sec-0022}
-------------------------------------------------------

As there is a tight coupling of intracellular calcium homeostasis and mitochondrial‐associated signalling, we evaluated whether Yo antibody internalization alters the function of NCX. NCX exchange of Ca^2+^ for Na^+^ is essential for neurone survival and associated with plasma and mitochondrial membranes [25](#nan12492-bib-0025){ref-type="ref"}, [26](#nan12492-bib-0026){ref-type="ref"}, [42](#nan12492-bib-0042){ref-type="ref"}. Under certain pathological conditions, NCX goes into reverse mode (NCX~rev~) and increases calcium entry into the cell by 30% [26](#nan12492-bib-0026){ref-type="ref"} with deleterious consequences for cellular homeostasis [25](#nan12492-bib-0025){ref-type="ref"}. We found that at PCD onset NCX~rev~ antagonist *KB‐R7943* (KB‐R, 10 μM) [43](#nan12492-bib-0043){ref-type="ref"}, [44](#nan12492-bib-0044){ref-type="ref"}, or NCX antagonists *CGP37157* (CGP, 10 μM) or *benzamil* (Benz, 250 nM) [42](#nan12492-bib-0042){ref-type="ref"}, reduced depletion of calbindin‐immunoreactive cells by up to 60% when co‐applied with Yo^+^ PCD sera or antibody against CDR2L (Figure [6](#nan12492-fig-0006){ref-type="fig"} **A**,**B**). Interestingly, the depletion of calbindin‐immunoreactive cells induced by CDR2 antibody binding was not affected by KB‐R7943 and CGP37157. In control slices, however, blocking NCX~rev~ with KB‐R7943 did cause strong depletion of calbindin‐immunoreactive cells (53.2 ± 6.2%; *P* \< 0.001), whereas the blockage of NCX with CGP37157 or benzamil did not affect the Calb^+^ cell count (Figure [6](#nan12492-fig-0006){ref-type="fig"} **B**).

![Yo antibody binding to CDR2L deregulates Na^+^/Ca^2+^ exchanger (NCX) signalling. **(A**,**B**) Calb^+^ cells per mm^3^ in cerebellar organotypic slice culture in response to treatment with anti‐Yo/rCDR and co‐treatment with KB‐R7943 (KB‐R, *n* = 4), CGP37157 (CGP, *n* = 4) and benzamil (Ben, *n* = 3). The anti‐Yo/rCDR pathology and its correlation to the antagonistic effects on NCX (CGP, Benz) itself or its reverse mode (KB‐R) showed a significant reduction of the depletion of calbindin‐immunoreactive cells for (**A**) Yo‐positive sera as well as (**B**) anti‐rCDR2L and anti‐rCDR2/2L but not for anti‐rCDR2 treatment. NCX inhibitor benzamil abolished Calb^+^ cell loss completely under anti‐Yo~4~ as well as anti‐rCDR2L and anti‐rCDR2/2L. Data are collected at treatment day 6 and expressed as mean ± SEM \[\**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001; nonparametric two‐tailed paired Mann--Whitney\'s *U*‐test; asterisk (\*): significance to naive control; hash (\#): significance to anti‐Yo/rCDR\].](NAN-45-141-g006){#nan12492-fig-0006}

Discussion {#nan12492-sec-0023}
==========

*Ex vivo* PCD model {#nan12492-sec-0024}
-------------------

The *ex vivo* PCD model used, makes it possible to study *in vivo* Yo antibody‐induced pathology [45](#nan12492-bib-0045){ref-type="ref"}, [46](#nan12492-bib-0046){ref-type="ref"} without the complexities of the blood--brain barrier and an active immune system [45](#nan12492-bib-0045){ref-type="ref"}, [47](#nan12492-bib-0047){ref-type="ref"}. The Yo antibody‐positive sera contained active complement factors, whereas the affinity‐purified rabbit CDR antibodies (rCDR) were used to perform neutral IgG antibody assay without exposing the cOTSC to any related peptides which could activate brain naive‐resident T cells [47](#nan12492-bib-0047){ref-type="ref"}. Both of these approaches led to identical depletion of the functional biomarker calbindin [28](#nan12492-bib-0028){ref-type="ref"}, [29](#nan12492-bib-0029){ref-type="ref"}, [31](#nan12492-bib-0031){ref-type="ref"}, [32](#nan12492-bib-0032){ref-type="ref"}, [48](#nan12492-bib-0048){ref-type="ref"}, [49](#nan12492-bib-0049){ref-type="ref"} in Purkinje neurons indicating that PCD is predominantly an antibody‐driven neurodegenerative disease. The Yo/CDR antibodies were clearly internalized by Purkinje neurons and caused a loss of calbindin immunoreactivity, whereas age‐/sex‐matched sera without Yo antibody or antibodies against Purkinje cell‐specific protein 2 (PCP2) or ataxia‐related GAD65 were not internalized and did not affect the immunoreactivity of biomarker calbindin.

Yo antibody‐induced pathology can be linked to the disturbance of calcium‐sensitive mitochondrial‐associated signalling {#nan12492-sec-0025}
-----------------------------------------------------------------------------------------------------------------------

Calbindin is the major modulator and buffer of Purkinje neurone intracellular calcium [28](#nan12492-bib-0028){ref-type="ref"}, [32](#nan12492-bib-0032){ref-type="ref"}, and calbindin depletion has been linked to neurodegeneration in PCD [29](#nan12492-bib-0029){ref-type="ref"}, Parkinson\'s disease [21](#nan12492-bib-0021){ref-type="ref"} and Alzheimer\'s disease [30](#nan12492-bib-0030){ref-type="ref"}. We have shown that calbindin co‐immunoprecipitated with CDR2, but not with CDR2L [20](#nan12492-bib-0020){ref-type="ref"}, which suggests that calbindin could stabilize both CDR2 expression and function. This has been recently confirmed by others [21](#nan12492-bib-0021){ref-type="ref"}. We have also demonstrated that Yo antibody binding to CDR2 and CDR2L leads to dysregulation of the calcium‐dependent VGCC‐PKC‐calbindin signalling pathway and calpain‐2 over‐activation, suggesting that cellular calcium overload plays an important role in Purkinje neurone degeneration and cerebellar atrophy in PCD [20](#nan12492-bib-0020){ref-type="ref"}. In Parkinson\'s disease, CDR2 expression is modulated by calpain‐ and ROS‐activity [21](#nan12492-bib-0021){ref-type="ref"}. PKC‐related kinase 1, an important factor in Alzheimer\'s disease and amyotrophic lateral sclerosis [50](#nan12492-bib-0050){ref-type="ref"}, interacts with CDR2 by phosphorylation [51](#nan12492-bib-0051){ref-type="ref"}.

As intracellular calcium homeostasis and mitochondrial‐associated signalling are strongly interdependent, sustained perturbations in this network can have devastating consequences to the cell. As neurons have high energy requirements, they are especially vulnerable to mitochondrial dysfunction, and we have found that Purkinje neurons display the highest mitochondria density of cells in the cerebellum (unpublished results). In the present study, we found that anti‐Yo internalization enhanced ROS production and lowered the mitochondrial membrane potential (ΔΨm) to similar levels as the protonophore uncoupler FCCP and BAM15. The rate of ROS production, ΔΨm and the activity of the electron transport chain complex are highly interdependent [27](#nan12492-bib-0027){ref-type="ref"}. We believe that anti‐Yo internalization not only downregulates ΔΨm and increases ROS generation through inhibition of respiration, it is also affecting the cation inward and anion outward transport of mitochondrial and plasma membrane to counteract calcium overload [52](#nan12492-bib-0052){ref-type="ref"}. Protonophore uncoupler FCCP does depolarize both mitochondrial and plasma membranes and thus causes and rapid collapse of calcium homeostasis within neurons [34](#nan12492-bib-0034){ref-type="ref"}, [35](#nan12492-bib-0035){ref-type="ref"}, as was indicated by the increased MTROS fluorescence levels under FCCP in our study. The specific depolarization of only the mitochondrial membrane by BAM15 did not show such an effect on the ROS output.

In the present study, we used the *ex vivo* PCD model to evaluate clinically used compounds that could possibly modulate the Purkinje neurone calcium homeostasis, as mitochondrial calcium overload, ROS signalling/production and MPTP opening are several key steps in neurodegeneration [22](#nan12492-bib-0022){ref-type="ref"}, [23](#nan12492-bib-0023){ref-type="ref"}, [25](#nan12492-bib-0025){ref-type="ref"}, [26](#nan12492-bib-0026){ref-type="ref"}. Mitochondrial calcium overload can be caused by increased VDAC and NCX~rev~ mitochondrial calcium influx, reduced NCX mitochondrial calcium efflux, and changes in mitochondrial calcium buffering capacity through MPTP opening [23](#nan12492-bib-0023){ref-type="ref"}. Prolonged opening of MPTP, a voltage and calcium‐dependent, CsA‐sensitive, high conductance channel is associated with increased inner mitochondrial membrane permeability. Depolarization of the inner mitochondrial membrane leads to respiratory chain dysfunction and is associated with increased ROS production [27](#nan12492-bib-0027){ref-type="ref"} as we have recorded with MTDR and MTROS after anti‐Yo was internalized into Purkinje neurons.

We found that targeting the MPTP with CsA and KB‐R7943 [22](#nan12492-bib-0022){ref-type="ref"}, [44](#nan12492-bib-0044){ref-type="ref"}, the respiratory chain with CBD and KB‐R7943 [41](#nan12492-bib-0041){ref-type="ref"}, [43](#nan12492-bib-0043){ref-type="ref"}, VDAC and cytochrome‐C with CBD [41](#nan12492-bib-0041){ref-type="ref"} and ROS over‐production with BHT [38](#nan12492-bib-0038){ref-type="ref"} provided graded neuroprotective capacity during exposure and accumulation of Yo antibodies in Purkinje neurons (Figure [7](#nan12492-fig-0007){ref-type="fig"}) albeit these compounds did not prevent the internalization of Yo antibody into Purkinje neurons.

![Calcium flux regulation in Purkinje neurons. Schematic diagram illustrates important calcium flux regulators in Purkinje neurone calcium homeostasis and how the six used antagonists modulate calcium flux and reveal neuroprotective capacity in antibody‐dependent manner. Some of the used antagonists have multiple targets, and a total of eight calcium flux regulating processes were subdue: (1) mitochondria permeability transition pore opening by cyclosporin‐A (cyclophilin D‐dependent) and KB‐R7943 (cyclophilin D‐independent, grey), (2) voltage‐dependent anion channels (*VDAC*) activity by cannabidiol (CBD), (3) *respiratory chain* (RC) regulation indirectly by butylated hydroxytoluene (BHT) and KB‐R7943 (grey), (4) cytochrome‐c (*Cyt C*) production by CBD, (5) reactive oxygen species production by BHT and CBD, (6) Na^+^/Ca^2+^ exchanger (*NCX*) activity by CGP37157 and benzamil, (7) *NCX* ~*rev*~ activity by KB‐R7943 and (8) voltage‐gated calcium channels (*VGCC*) activity by CGP37157 and CBD. Balancing these eight calcium‐sensitive targets resulted in moderate (single arrow) to high (triple arrows) neuroprotective effects during anti‐Yo/rCDR internalization, with one exception. In Purkinje neurone degeneration caused by anti‐rCDR2, inhibition of NCX (process 6) or its reverse mode (process 7) showed no beneficial effect (ø). Indirect inhibitory effects are marked in grey.](NAN-45-141-g007){#nan12492-fig-0007}

Although CsA is used clinically, there are caveats to its use especially as it does not efficiently cross the blood--brain barrier [53](#nan12492-bib-0053){ref-type="ref"}. It is unlikely therefore to be an effective neuroprotective agent in the cerebellum *in vivo*. However, we show that CsA has a beneficial effect on the mitochondrial membrane potential without affecting the ROS release when anti‐Yo was internalized in Purkinje neurons. Furthermore, because of its immunosuppressive properties and ability to induce necrosis in breast cancer cells by downregulating PKM2 expression and ATP synthesis [54](#nan12492-bib-0054){ref-type="ref"}, CsA may still have a potential for use in PCD therapy.

The seconded tested clinical compound, CBD, is not only a low potency CB1R inverse agonist, but potentially targets multiple calcium signalling modulators such as the respiratory chain, VDACs and cytochrome‐C [41](#nan12492-bib-0041){ref-type="ref"}, [55](#nan12492-bib-0055){ref-type="ref"}, [56](#nan12492-bib-0056){ref-type="ref"}. Furthermore, it has anti‐inflammatory and antioxidant properties, and interferes with tumour neovascularization, cancer cell migration, adhesion and invasion [57](#nan12492-bib-0057){ref-type="ref"}. We found that CBD can minimize the downgrading of the mitochondrial membrane potential if Yo pathology occurs; however, CBD also potentiated the anti‐Yo‐induced ROS production boost probably due to its modulatory property towards the respiratory chain. Furthermore, CBD can easily cross the blood--brain barrier because of its lipophilic nature. CB1Rs are highly expressed in the cerebellum [40](#nan12492-bib-0040){ref-type="ref"} and their activation reduces neurotransmitter release at all major classes of Purkinje neurone synapses [58](#nan12492-bib-0058){ref-type="ref"}. The results obtained with CBD and AM281 treatment suggest that Yo antibody binding mainly to CDR2 causes a reduced neurotransmitter release [58](#nan12492-bib-0058){ref-type="ref"} and sparse neural activity due to CB1R over‐activation [59](#nan12492-bib-0059){ref-type="ref"}. Under normal physiological conditions, blocking CB1Rs can, however, disrupt neuronal activity and cause neurodegeneration [59](#nan12492-bib-0059){ref-type="ref"} as we observed in the experimental controls. Currently, an oromucosal spray containing CBD is in clinical use to treat moderate to severe spasticity in multiples sclerosis [60](#nan12492-bib-0060){ref-type="ref"} which might be used as a first step towards a CBD‐based PCD therapy (Figure [7](#nan12492-fig-0007){ref-type="fig"}).

The effect of CsA and CBD both support mitochondrial dysfunction as a major factor in PCD, which is also supported by the effect of ROS scavenger BHT data. Similar to observations in Parkinson\'s disease, where CDR2 expression is modulated by calpain and ROS activity [21](#nan12492-bib-0021){ref-type="ref"} we showed earlier that Yo antibody internalization alters the activity of calpain [20](#nan12492-bib-0020){ref-type="ref"} and now the ROS output. These findings indicate that binding of Yo antibodies to CDR2 and CDR2L potentially affects the complex I of the respiratory chain, a known site for increased ROS production [27](#nan12492-bib-0027){ref-type="ref"}.

Targeting the calcium efflux regulator NCX that regulates not only cytosolic calcium efflux, but also mitochondrial calcium homeostasis with CGP37157 [26](#nan12492-bib-0026){ref-type="ref"}, [42](#nan12492-bib-0042){ref-type="ref"} or KB‐R7943 [43](#nan12492-bib-0043){ref-type="ref"}, [44](#nan12492-bib-0044){ref-type="ref"} revealed deregulation after anti‐Yo internalization and a significant difference in the neuropathological processes induced by Yo antibody binding to CDR2 and CDR2L, respectively. NCX blockage failed to block the loss of calbindin immunoreactivity induced by Yo antibody binding to CDR2 but did reduce the depletion of calbindin‐immunoreactive cells induced by Yo binding to CDR2L. This supports our previous findings that functionally linked CDR2L to membrane‐associated signalling [20](#nan12492-bib-0020){ref-type="ref"}. Although KB‐R7943 is mainly known as an NCX~rev~ antagonist, it is also reported to modulate calcium flux by modulating the opening of MPTPs independently of cyclophilin D, L‐type VGCC, ryanoidine receptors, store‐operated calcium entry [44](#nan12492-bib-0044){ref-type="ref"} and mitochondrial complex I [43](#nan12492-bib-0043){ref-type="ref"}. KB‐R7943 influences mitochondrial calcium handling by increasing the calcium retention capacity, which can protect mitochondrial function from pathological calcium overload [44](#nan12492-bib-0044){ref-type="ref"}. Therefore, the nonresponse of anti‐CDR2 pathology to KB‐R7943 indicates that CDR2 binding does not alter the mitochondrial calcium retention capacity or the cyclophilin D‐independent opening of MPTPs.

We show that the binding of the Yo antibody (ies) to the assigned antigens CDR2 or CDR2L initiates different pathological cascades in the cerebellum, especially in Purkinje neurons. Our data indicate that not so much the antibody concentration [20](#nan12492-bib-0020){ref-type="ref"} more like the ratio of Yo binding to CDR2 or CDR2L influences the effectiveness of each antagonistic neurodegenerative treatment strategy.

Conclusion {#nan12492-sec-0026}
==========

Taken together, our data indicate that Yo antibody incorporation into Purkinje neurons causes multiple alterations regarding mitochondrial and cytosolic calcium influx/efflux regulation: CB1R activity, MPTP opening, mitochondrial membrane potential, ROS output or NCX calcium influx/efflux regulation. Thus, anti‐Yo‐induced pathology can be beneficially modulated by clinical used compounds such as CsA, CBD and ROS scavenger BHT.

However, our study is solely based on neuropharmacological manipulation where the used compounds can interfere with more than one signalling pathway, for that reason we have provided only a first indication that mitochondrial dysfunction occurs if autoantibody Yo is internalized into Purkinje neurons. Further molecular biological studies have to be done to characterize the precise mechanistic alterations, for example, alteration of the complex I of the respiratory chain, to deepen our knowledge on mitochondrial‐associated autoimmune‐mediated neurodegeneration.

As current immunomodulatory therapies for Yo antibody‐mediated PCD are not very effective [33](#nan12492-bib-0033){ref-type="ref"}, [61](#nan12492-bib-0061){ref-type="ref"}, additional therapeutic strategies addressing in particular the Purkinje neurone degeneration are important for future PCD therapy and our findings demonstrate that treatment addressing calcium homeostasis imbalance and ROS over‐production seems to provide neuroprotective potential.
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